Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
暂无分享，去创建一个
B. Monk | B. van Calster | R. Wenham | I. Vergote | N. Colombo | G. Scambia | C. Marth | A. Bamias | J. Kroep | A. Covens | W. Meier | D. O’Malley | Sang-Yoon Park | J. D. Del Campo | Haijun Ma | C. A. Pickett | M. Raza Mirza | B. Van calster